OpGen Announces Interim Analysis Results from Clinical Trial for Unyvero Urinary Tract Infection Panel
April 05, 2022 07:30 ET
|
OpGen, Inc.
Interim analysis performed with initial 150 U.S. patient samples enrolled in its prospective multicenter trial for the Unyvero UTI panel - Clinical Trial to be continued without any...
OpGen Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
March 29, 2022 16:05 ET
|
OpGen, Inc.
Total revenue for 2021 was approximately $4.3 millionStrong total cash position of approximately $36.1 million as of December 31, 2021, up significantly from $13.4 million at year-end 2020Conference...
OpGen to Provide Business Update and Financial Results for the Fourth Quarter and Full Year 2021 on March 29th at 4:30 p.m. Eastern Time
March 15, 2022 07:30 ET
|
OpGen, Inc.
ROCKVILLE, Md., March 15, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its fourth quarter...
OpGen Announces Publication of Results from the Acuitas AMR Gene Panel Multicenter Clinical Trial in the Journal of Clinical Microbiology
February 10, 2022 16:30 ET
|
OpGen, Inc.
Publication demonstrates FDA cleared Acuitas AMR Gene Panel detects and differentiates a broad range of 28 AMR markers that can be associated with up to 9 antimicrobial classes Provides results at...
OpGen Announces Successful Completion of Unyvero A30 Development Milestone
February 10, 2022 07:30 ET
|
OpGen, Inc.
Unyvero A30 RQ analyzer successfully completed verification and validation (V&V) testing as well as lifetime testingUnyvero A30 instruments met all V&V criteria for series-production systems ...
OpGen to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference from January 25-27th, 2022
January 18, 2022 07:30 ET
|
OpGen, Inc.
ROCKVILLE, Md., Jan. 18, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat...
OpGen Announces Preliminary Unaudited Revenue for Fiscal 2021 and Provides Business Update
January 10, 2022 07:30 ET
|
OpGen, Inc.
Preliminary unaudited revenue for 2021 was approximately $4.3 millionMaintained strong balance sheet with $36.1 million cash as of December 31, 2021 and total capital raised in 2021 of $51.2...
OpGen subsidiary Ares Genetics announces the strategic expansion of ARESdb proprietary contents
December 14, 2021 07:30 ET
|
OpGen, Inc.
Following successful completion of Phase 1, Ares Genetics has now entered into Phase 2 of its collaboration with a leading U.S. CRO and reference lab, gaining access to 1,000 proprietary clinical...
OpGen Announces Results of Special Meeting of Stockholders
December 08, 2021 16:30 ET
|
OpGen, Inc.
ROCKVILLE, Md., Dec. 08, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and informatics to...
OpGen Subsidiary Ares Genetics Announces Strategic Database Access Transaction
November 30, 2021 08:45 ET
|
OpGen, Inc.
Ares Genetic is granting a permanent, unrestricted and non-exclusive access to a small subset of the proprietary ARESdb data asset to an unnamed global corporation and leader in microbiology and...